Czech National Bank Purchases 989 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Czech National Bank lifted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.6% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 28,442 shares of the biopharmaceutical company’s stock after purchasing an additional 989 shares during the quarter. Czech National Bank’s holdings in Regeneron Pharmaceuticals were worth $17,735,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. Brighton Jones LLC increased its stake in Regeneron Pharmaceuticals by 261.8% during the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock valued at $675,000 after purchasing an additional 686 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new position in shares of Regeneron Pharmaceuticals in the first quarter valued at $226,000. Arrowstreet Capital Limited Partnership acquired a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at about $3,183,000. Gabelli Funds LLC increased its position in shares of Regeneron Pharmaceuticals by 3.0% during the second quarter. Gabelli Funds LLC now owns 1,863 shares of the biopharmaceutical company’s stock worth $978,000 after acquiring an additional 55 shares in the last quarter. Finally, Sei Investments Co. raised its holdings in shares of Regeneron Pharmaceuticals by 18.8% in the 2nd quarter. Sei Investments Co. now owns 32,341 shares of the biopharmaceutical company’s stock worth $16,985,000 after acquiring an additional 5,120 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 200 shares of the business’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total value of $130,030.00. Following the transaction, the director directly owned 17,303 shares in the company, valued at $11,249,545.45. The trade was a 1.14% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is currently owned by insiders.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $784.36 on Friday. The stock has a 50 day moving average of $657.28 and a 200 day moving average of $712.33. The company has a market capitalization of $82.92 billion, a price-to-earnings ratio of 19.39, a PEG ratio of 1.32 and a beta of 0.22. Regeneron Pharmaceuticals, Inc. has a 12 month low of $541.00 and a 12 month high of $821.11. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.16 by $4.13. The firm had revenue of $4.29 billion during the quarter, compared to the consensus estimate of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The business’s revenue for the quarter was up 16.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $12.81 EPS. As a group, sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th will be given a $0.94 dividend. The ex-dividend date of this dividend is Tuesday, August 18th. This represents a $3.76 annualized dividend and a yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is currently 9.29%.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Barclays maintained its Buy rating on Regeneron. The reaffirmed bullish view provides support for REGN, particularly after the company’s recent earnings beat, which included revenue growth and earnings per share well above consensus. Barclays Keeps Their Buy Rating on Regeneron
• Neutral Sentiment: Intellia Therapeutics reported lower revenue because of reduced Regeneron collaboration revenue. Intellia’s second-quarter revenue declined 46.2%, but the item reflects Intellia’s financial results rather than a newly announced change in Regeneron’s pipeline or partnership strategy. NTLA Q2 Earnings In Line, Top Line Misses on Lower Regeneron Revenues
• Negative Sentiment: Several law firms reiterated notices about a pending securities class action against Regeneron. The lawsuit concerns alleged disclosure issues surrounding the failed Phase 3 melanoma trial, which reportedly led to a substantial market-value loss. Investors who purchased REGN shares during the August 1, 2025–May 15, 2026 class period have until September 14, 2026 to seek lead-plaintiff status. The repeated notices add legal and reputational risk but do not indicate a new lawsuit-related financial liability. Regeneron Class Action Lawsuit Deadline Notice

Analyst Upgrades and Downgrades

REGN has been the subject of a number of analyst reports. Weiss Ratings reiterated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Wednesday, June 24th. Benchmark raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 price objective for the company in a research note on Tuesday, July 7th. Wall Street Zen raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. Citigroup upped their price target on Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the stock a “neutral” rating in a report on Monday, August 3rd. Finally, Wells Fargo & Company increased their price target on Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the company an “equal weight” rating in a research report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and ten have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $797.75.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.